We are in uncharted waters and risk is extremely high for the financial markets at the moment. Investors in biotech and beyond will have a lot to consider in the next few days. Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
[from today’s edition of Smart Tech 50 Weekly Movers]Dyax Corp. (DYAX) received a $5.9 billion dollar buyout offer from Shire Pharmaceuticals. The stock, early on Monday morning (11/2/15) was trading above $36 per share, a nearly 33% premium over the 10/30/15 closing price. We recommend sale of the shares for… Read More
[from today’s edition of Smart Tech 50 Weekly Movers]Dyax Corp. (DYAX) received a $5.9 billion dollar buyout offer from Shire Pharmaceuticals. The stock, early on Monday morning (11/2/15) was trading above $36 per share, a nearly 33% premium over the 10/30/15 closing price. We recommend sale of the shares for… Read More
[from today’s edition of Smart Tech 50 Weekly Movers]Celldex Therapeutics (CLDX) is almost an EBIS stock. The company is working on a vaccine for aggressive brain cancers. It has plenty of money on its balance sheet but is high risk and has not been able to make money consistently. Read More
[from today’s edition of Smart Tech 50 Weekly Movers]Celldex Therapeutics (CLDX) is almost an EBIS stock. The company is working on a vaccine for aggressive brain cancers. It has plenty of money on its balance sheet but is high risk and has not been able to make money consistently. Read More
[from today’s issue of Smart Tech Investor]Cambrex Corp. (CBM) manufactures active pharmaceutical ingredients for brand name and generic drugs that treat pain management, cardiovascular, central nervous system, endocrine, gastrointestinal, skin, respiratory and urinary conditions. The company specializes in all areas of development and manufacturing from the transition from research and… Read More
[from today’s issue of Smart Tech Investor]Cambrex Corp. (CBM) manufactures active pharmaceutical ingredients for brand name and generic drugs that treat pain management, cardiovascular, central nervous system, endocrine, gastrointestinal, skin, respiratory and urinary conditions. The company specializes in all areas of development and manufacturing from the transition from research and… Read More
- October 19, 2015
-
Download Issue
A picture is worth a thousand words. And, believe it or not, the odds of a biotech rally may be on the rise. We’ll note right here and now, that it is quite possible that we’re wrong given the potential for nasty earnings surprises or any other external events that… Read More
A picture is worth a thousand words. And, believe it or not, the odds of a biotech rally may be on the rise. We’ll note right here and now, that it is quite possible that we’re wrong given the potential for nasty earnings surprises or any other external events that… Read More
Neurocrine Biosciences (NBIX) reported a net loss of $24.0 million, or $0.28 loss per share, compared to a net loss of $13.4 million, or $0.18 loss per share, for the same period in 2014. For the six months ended June 30, 2015, the Company reported a net loss of $25.2… Read More